News
Nigerian Firm Ash Biomedical Unveils Seven Tests For HIV, Malaria, Hepatitis
A Nigerian firm, Ash Biomedical Diagnostics Ltd., has announced the production of seven of its own-brand diagnostic medicine to manage and treat HIV, malaria, hepatitis, and pregnancy.
The seven products include ABD HIVChek, MalChek, MalChek Plus, HepaQuik, HepaQuik Duo, PregSure, and FlaviQuik.
The products comprise 12 Stock Keeping Units (SKUs) covering four critical healthcare testing areas including HIV, malaria, hepatitis, and pregnancy.
Its Managing Director, Adetoyese Shodeinde, in a statement issued Monday, stressed that the achievement reflected years of deliberate investment in quality, regulatory compliance, and product development.
Shodeinde explained that among the newest additions now available nationwide were FlaviQuik, designed for Hepatitis C rapid testing, and HepaQuik Duo, which enables dual screening for Hepatitis B and Hepatitis C using one test, supporting healthcare providers and screening programmes in identifying individuals who may require further medical evaluation during a single patient encounter.
Shodeinde said for Nigerians, the significance of the milestone extended beyond product availability, adding that it represents continued progress towards strengthening confidence in locally developed healthcare solutions while expanding access to rapid diagnostics capable of supporting earlier disease detection.
He stressed that NAFDAC registration provided the formal regulatory basis for the products to be marketed in Nigeria.
Shodeinde added, “Our vision has always been bigger than producing diagnostic kits. We are building confidence in Nigerian healthcare manufacturing by ensuring that every product carrying the Ash Biomedical name meets the standards required for quality, reliability and national regulatory approval.”
He stated that Ash Biomedical’s expanded hepatitis portfolio arrived as increased hepatitis screening continued to draw national and global attention.
Related
